Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. - Wikidata - awgldk - TriplyDB

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

http://www.wikidata.org/entity/Q34949678

about

Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinoma Evolving concepts in cancer therapy through targeting sphingolipid metabolism Characterization of isoenzyme-selective inhibitors of human sphingosine kinases The impact of sphingosine kinase-1 in head and neck cancer.Re-configuration of sphingolipid metabolism by oncogenic transformation.Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.Interdiction of sphingolipid metabolism to improve standard cancer therapies.Apoptotic sphingolipid ceramide in cancer therapy.Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.Development of small-molecule inhibitors of sphingosine-1-phosphate signaling Sphingosine-1-phosphate signaling and its role in disease.Targeting sphingosine kinase-1 to inhibit melanoma.Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesin phosphorylation and cancer cell invasion.The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.Novel chemotherapeutic drugs in sphingolipid cancer research.Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy Novel pharmacological modulators of autophagy and therapeutic prospects.A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration.Targeting sphingosine-1-phosphate signaling for cancer therapy.Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.Increased SPHK2 Transcription of Human Colon Cancer Cells in Serum-Depleted Culture: The Involvement of CREB Transcription Factor.A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.

P2860

Q26744051-36FB52F7-0A32-4F99-93E1-39EB3E780F58 Q26863646-4583B3E6-C6E8-40B9-A58B-50495496B225 Q28483643-084C4B37-1360-4168-8EA6-D24A31A0F600 Q33649748-50F999A0-3B0E-455B-AF75-46F6A4560FC3 Q33649823-9AA89632-07DB-4D31-AD39-2647E582137F Q34209320-2390D16B-AF54-4D5C-A1D7-CD9C9282FEE0 Q34214476-790B7735-C904-4247-90C1-2597E139A732 Q34373466-493C6B68-B0BB-465B-8ED0-3A94CAA0209C Q34736760-C1A31030-FAD7-4560-A9DF-F55D09DD31C2 Q34928923-42010660-413A-4F94-A3D7-BF125AE3ABCF Q35489007-0F0176A7-50B3-4ABF-B282-5257C0BE8228 Q35661485-9D62057D-AE0F-477E-B1B7-B7F2401AAC0B Q35789935-B4A5BB36-5177-48FD-9411-822044404DD1 Q36171317-565BD7F0-EEC6-4001-886E-CD9216F25AC8 Q36359489-E8E85E5E-0F67-4629-8B92-8772887A2AA7 Q37190258-479EB801-CBFC-498C-A13D-3E1E03A43166 Q37721276-42C2EE6E-E19A-4378-92D1-F477948EA3AF Q37905015-90DAB5DB-9CC2-4805-B4CE-27679A54DD82 Q38031895-9CF7D110-7DBE-46F8-9908-A7270702C64B Q38632417-153D9C58-5331-4960-81E5-4CF0CAF49E6C Q38843958-0AFDB09F-E5AC-4186-8743-E581EFDC089F Q38915115-2F28ABC8-7AF2-4F7D-BC1D-8CDC2C46828B Q39215469-52C86FEE-8408-45EA-A0C2-39C22715DF7E Q39379449-44624624-863A-48FB-B9ED-EA5B7B7B4F89 Q39496138-E73C5484-2D5B-4748-A668-B381507FF6EA Q51496711-329EF1F8-CBC7-4D39-8507-FF7A56382060 Q55001442-231600B8-B63C-4E12-8EE4-F3CE53C92B96

P2860

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

http://www.wikidata.org/entity/Q34949678

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@ast

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@en

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@nl

type

label

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@ast

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@en

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@nl

prefLabel

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@ast

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@en

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@nl

P1433

Q34949678-B977EE87-E354-41D0-949F-9CF3ABFBE6BD

P1476

Q34949678-AF5EEEF4-B73D-460C-8D33-A9DAA2614F93

P2093

Q34949678-9D25BDC5-3674-4E2D-A050-8CD69B065515

Q34949678-9E14B2D3-D98C-400A-ABF2-D222765F0A74

Q34949678-CE1EF699-C1E8-41C0-AC2D-F00FCC0153B0

Q34949678-D11F35E5-D436-4EFF-9A01-D3AE666E09A2

P2860

Q34949678-024691A1-F45D-4DC6-8DD3-FC4665044172

Q34949678-05791FF9-3D40-46BA-A28B-5A740452CE3B

Q34949678-074EF96C-F5C1-4D35-9BAD-7392C6566BD2

Q34949678-102BBA4D-7744-488F-BE67-47478238F24E

Q34949678-15E395FF-F8D7-4004-919F-45A3A050A16B

Q34949678-22442234-28A7-4409-B172-A8BB8C61B03F

Q34949678-2B89C866-52B1-4CD2-9F7E-51F1F6730341

Q34949678-2E9DB8EB-B6EF-466D-827E-06B51FC6C334

Q34949678-3DAC3B65-4498-455F-98DE-FB211CD702C4

Q34949678-40EE141B-816D-4795-BE8C-1C38DC04467D

P2888

Q34949678-BEA96199-CE15-4FC8-8117-796B7C8AEE26

P304

Q34949678-4BB1DD58-8C7A-4375-BD2F-D1B2AD7094AB

P31

Q34949678-627BBA4E-6429-40F8-BE48-290AC9BBD9E3

P356

Q34949678-719FE749-ED05-45FE-935E-54E2E920F792

P433

Q34949678-71CA2034-986B-419D-BC01-34BE1913E12E

P478

Q34949678-E2CEDC0E-C50A-4B97-9A21-DE668D76ADD7

P577

Q34949678-737FAA80-BBFE-446F-8EA2-5C39DBFA4DDC

P5875

Q34949678-EFDCE228-2674-4431-8D78-4EF8140D43D3

P6179

Q34949678-225991C2-8091-4753-AAD4-380D1C44681A

P698

Q34949678-95CF1CE7-BB48-4089-B64C-2CC346142BCA

P932

Q34949678-1240E0AC-87B3-4FA9-9D92-92AB11D06004

P356

S10637-010-9452-0

P1433

Investigational New Drugs

P1476

Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

@en

P2093

Charles D Smith

http://www.w3.org/2001/XMLSchema#string

Christian Knaak

http://www.w3.org/2001/XMLSchema#string

Vladimir Beljanski

http://www.w3.org/2001/XMLSchema#string

Yan Zhuang

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase

A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity

Roles of bioactive sphingolipids in cancer biology and therapeutics

Raf kinase as a target for anticancer therapeutics

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

New colorimetric cytotoxicity assay for anticancer-drug screening

Discovery and evaluation of inhibitors of human sphingosine kinase.

Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2

P2888

s10637-010-9452-0

P304

1132-1142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-010-9452-0

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44602945

http://www.w3.org/2001/XMLSchema#string

P6179

1006728357

http://www.w3.org/2001/XMLSchema#string

P698

20473784

http://www.w3.org/2001/XMLSchema#string

P932

3089696

http://www.w3.org/2001/XMLSchema#string